Full Press Release Details
NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical” or the "Company”) (NASDAQ: OM). Outset Medical is a medical technology company that develops a hemodialysis system for kidney patients.
On June 13, 2022, after the market closed, Outset Medical announced that it halted shipments of its Tablo Hemodialysis System for home use pending the U.S. Food and Drug Administration's (FDA) review and clearance of a 510(k) the company submitted for changes made since the device's original clearance. Outset Medical also suspended its prior fiscal 2022 guidance.
Following this news, shares of Outset Medical fell significantly in after-hours trading on June 13, 2022, and dropped more than 30% when the market opened on June 14, 2022.
If you purchased or otherwise acquired Outset Medical securities and would like to discuss our investigation, please contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, your rights, or your interests, please contact:
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
E-mail: dhall@kaplanfox.com
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com